Holen Sie sich die Stockscreener-App
11.72
2.54%
0.29
Handel nachbörslich:
11.72
Schlusskurs vom Vortag:
$11.43
Offen:
$11.5
24-Stunden-Volumen:
11,504
Relative Volume:
0.08
Marktkapitalisierung:
$225.16M
Einnahmen:
$54,000
Nettoeinkommen (Verlust:
$-210.26M
KGV:
-14.84
EPS:
-0.79
Netto-Cashflow:
$-159.01M
1W Leistung:
+5.59%
1M Leistung:
+3.08%
6M Leistung:
-16.71%
1J Leistung:
-57.54%
1-Tages-Spanne:
$11.21
$11.72
1-Wochen-Bereich:
$10.76
$11.72
52-Wochen-Spanne:
$7.65
$32.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Firmenname
Lyell Immunopharma Inc
Sektor
Branche
Telefon
650 695-0677
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Vergleichen Sie LYEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
11.72 | 219.20M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-30 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-06-27 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | BofA Securities | Buy |
| 2021-07-12 | Eingeleitet | Goldman | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-12 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten
Using Bollinger Bands to evaluate Lyell Immunopharma Inc.Entry Point & Short-Term Trading Opportunity Alerts - Newser
Will Lyell Immunopharma Inc. stock go up soonJuly 2025 Trends & Community Consensus Picks - Newser
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-To-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma - MarketScreener
Lyell Immunopharma Announces the Initiation of a Phase 3 - GlobeNewswire
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee - Stock Titan
Price action breakdown for Lyell Immunopharma Inc.Bond Market & Real-Time Stock Price Movement Reports - Newser
Using RSI to spot recovery in Lyell Immunopharma Inc.July 2025 EndofMonth & Real-Time Sentiment Analysis - Newser
What the charts say about Lyell Immunopharma Inc. today2025 Short Interest & Consistent Profit Alerts - Newser
Order flow analysis tools used on Lyell Immunopharma Inc.Market Risk Analysis & Consistent Return Strategy Ideas - Newser
Using data models to predict Lyell Immunopharma Inc. stock movementWatch List & Technical Buy Zone Confirmation - Newser
Sector ETF performance correlation with Lyell Immunopharma Inc.Forecast Cut & Precise Buy Zone Identification - Newser
Lyell Immunopharma’s Strategic Momentum in CAR T-Cell Innovation and Commercial Readiness - AInvest
Can Traders Expect Breakout From Lyell Immunopharma Inc. This Week getLinesFromResByArray error: size == 0 - kangso.co.kr
Is Lyell Immunopharma Inc. in a bullish channelJuly 2025 Breakouts & High Accuracy Investment Signals - khodrobank.com
Lyell Immunopharma to Present at Investor Conferences - AInvest
Lyell Immunopharma Announces Participation in September Investor Conferences - GlobeNewswire
Clinical-Stage CAR T-Cell Therapy Developer Lyell Immunopharma Announces Key September Investor Presentations - Stock Titan
Is Lyell Immunopharma Inc. a good stock for dollar cost averagingJuly 2025 Opening Moves & Target Return Focused Stock Picks - khodrobank.com
What candlestick patterns are forming on Lyell Immunopharma Inc.Weekly Trade Analysis & Free Expert Approved Momentum Trade Ideas - Newser
Can Lyell Immunopharma Inc. reach all time highs this yearTrend Reversal & Smart Allocation Stock Reports - khodrobank.com
Multi factor analysis applied to Lyell Immunopharma Inc.2025 Trade Ideas & Scalable Portfolio Growth Ideas - Newser
Detecting price anomalies in Lyell Immunopharma Inc. with AIEarnings Overview Summary & AI Powered Market Entry Ideas - Newser
What technical models suggest about Lyell Immunopharma Inc.’s comebackCEO Change & Short-Term High Return Ideas - Newser
Detecting support and resistance levels for Lyell Immunopharma Inc.Entry Point & Safe Entry Momentum Stock Tips - Newser
Identifying reversal signals in Lyell Immunopharma Inc.July 2025 Analyst Calls & Daily Oversold Stock Bounce Ideas - Newser
Applying big data sentiment scoring on Lyell Immunopharma Inc.Market Activity Summary & Accurate Entry/Exit Alerts - Newser
Visual trend scoring systems applied to Lyell Immunopharma Inc.Stock Surge & Free Safe Entry Trade Signal Reports - Newser
What momentum shifts mean for Lyell Immunopharma Inc.Market Risk Summary & Entry Point Confirmation Alerts - Newser
Custom strategy builders for tracking Lyell Immunopharma Inc.Quarterly Portfolio Report & Smart Swing Trading Techniques - Newser
Real time scanner hits for Lyell Immunopharma Inc. explained2025 Pullback Review & Verified Momentum Watchlists - Newser
Regression analysis insights on Lyell Immunopharma Inc. performanceMarket Sentiment Report & Daily Momentum Trading Reports - Newser
How to escape a deep drawdown in Lyell Immunopharma Inc.July 2025 Highlights & AI Driven Price Predictions - Newser
Is Lyell Immunopharma Inc. a candidate for recovery playNew Guidance & Free Accurate Trade Setup Notifications - Newser
Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lyell Immunopharma Inc-Aktie (LYEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hill Stephen J. | Chief Operating Officer |
Aug 21 '25 |
Sale |
10.54 |
1,004 |
10,586 |
15,845 |
| Newton Charles W. | Chief Financial Officer |
Aug 21 '25 |
Sale |
10.54 |
1,453 |
15,320 |
15,306 |
| Lee Gary K. | Chief Scientific Officer |
Aug 21 '25 |
Sale |
10.54 |
1,453 |
15,320 |
15,504 |
| Seely Lynn | President and CEO |
Aug 12 '25 |
Sale |
10.34 |
406 |
4,197 |
34,828 |
| Seely Lynn | President and CEO |
Aug 11 '25 |
Sale |
10.53 |
391 |
4,116 |
35,234 |
| Hill Stephen J. | Chief Operating Officer |
Aug 12 '25 |
Sale |
10.34 |
94 |
972 |
8,849 |
| Hill Stephen J. | Chief Operating Officer |
Aug 11 '25 |
Sale |
10.53 |
91 |
958 |
8,943 |
| Lee Gary K. | Chief Scientific Officer |
Aug 12 '25 |
Sale |
10.34 |
136 |
1,406 |
8,957 |
| Lee Gary K. | Chief Scientific Officer |
Aug 11 '25 |
Sale |
10.53 |
131 |
1,379 |
9,093 |
| Newton Charles W. | Chief Financial Officer |
Aug 12 '25 |
Sale |
10.34 |
136 |
1,406 |
8,759 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):